Now Playing
|Videos|October 27, 2022
Understanding the Role of the COVID-19 Pandemic in Increased Substance Use Disorder: Opportunities for Pharmacist Intervention
An expert panel led by moderator Dr. Cunningham identify substance use disorder, COVID-19’s role, and opportunities for pharmacists to help patients with resources for recovery.
Advertisement
Please see PDF above for article related to this video.
Episodes in this series
Advertisement
Related to this article
Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
If gene therapies are expected to deliver decades of benefit, long-term evidence collection must be coordinated, useful to patients, and financially sustainable.
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
3
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
4
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
5